Introduction {#Sec1}
============

MitraClip is a treatment option for patients with symptomatic, moderate-severe to severe mitral regurgitation (MR) in whom risks of conventional surgery are too high \[[@CR1]--[@CR3]\]. However, not all patients have clinical benefit after a technically successful procedure \[[@CR4]--[@CR7]\]. Improvement of selection of patients who have clinical benefit from the MitraClip is needed as unnecessary harm to the patient should be avoided and resources are limited \[[@CR5], [@CR6]\]. The process of patient selection is complex because the majority of patients is frail, and suffer from comorbidities that also contribute to their symptoms, including pulmonary disease, coronary artery disease and end-stage heart failure \[[@CR8], [@CR9]\]. In addition, MR itself is often complex because of anatomic heterogeneity, large variation in etiologies (functional and degenerative MR) and varying response to exercise \[[@CR10]--[@CR12]\].

In literature, it was emphasized that the majority of patients experience symptoms during exercise, whereas most echocardiograms are performed in rest \[[@CR13]--[@CR16]\]. Some studies suggest that stress echocardiography might be useful for risk-stratification in patients with MR \[[@CR13], [@CR14], [@CR16]--[@CR19]\]. In these patients with MR, echocardiographic parameters, e.g. increase in systolic pulmonary artery pressure, increase in stroke volume and increase in MR severity during exercise, have been described to identify patients who were at higher risk of cardiovascular death \[[@CR13], [@CR18], [@CR19]\]. However, these studies were focused on conservatively treated patients with MR, while there is need for a risk-stratification tool in patients with MR who undergo a MitraClip procedure to improve future selection of patients.

The aim of the current study was to investigate whether stress echocardiography may improve the selection of patients who will have clinical benefit from percutaneous mitral valve repair with the MitraClip.

Methods {#Sec2}
=======

For this prospective study patients who were scheduled for MitraClip treatment between June 2015 and December 2016 were approached. In total, 39 patients gave written informed consent and underwent stress echocardiography prior to the MitraClip implantation. The study complied with the ethical guidelines of the 1975 Declaration of Helsinki regarding investigation in humans and was approved by the Medical Ethics Committee (NL52635.018.15).

Transthoracic low-dose stress echocardiography (Vivid E9; GE Healthcare, Horten, Norway) using handgrip and/or dobutamine were added to the preprocedural evaluation of the patients. Handgrip exercise was performed 3--5 min, depending on patients' capabilities. Initial dose of intravenous dobutamine was 5 µg/kg/min which was increased in phases of 3 min to 10 and 15 µg/kg/min. Patients were instructed to withhold their beta-blockers prior to the stress echocardiography. Changes in stroke volume (pulse wave Doppler apical 5 chamber view), ejection fraction (Simpson's rule biplane method) and MR grade were determined. Stroke volume was corrected for heart rate, with 75 beats per minute (bpm) as reference. MR severity was graded as none, mild (1), moderate (2), moderate to severe (3) or severe (4) based on qualitative, semiquantitative and quantitative parameters according to the ESC guidelines \[[@CR20]\]. Echocardiographic recordings were digitalized and analyzed offline. All echocardiographic measurements were performed by a single experienced investigator (JFV) and reviewed by an experienced sonographer (HAdB), both blinded for the clinical outcome.

Improvement after MitraClip implantation was assessed by New York Heart Association (NYHA) classification, Quality of Life (QoL) questionnaires, 6 min walk test (6MWT) and VO~2~ max cycling test (VO~2~ max). The QoL evaluation was based on the Minnesota Living with Heart Failure Questionnaire (MLHFQ), RAND Short Form-36 (SF-36) and EuroQol-5D (EQ-5D). The VO~2~ max cycling test started at a voltage of 0 W aiming for a test between 6 and 8 min. At follow-up, the same measurements were performed.

Baseline characteristics of the patients were entered into a dedicated, prospective database. All patients were invited for clinical evaluation and transthoracic echocardiography (TTE) at 1 month, 6 months and 12 months post MitraClip implantation. Patients were followed until either death or end of follow-up (29th of November 2017). Patients in whom implantation was technically successful were included in the analysis. A technically successful implantation was defined as a procedural reduction to MR grade ≤ 2. Clinical benefit from MitraClip treatment was defined as survival and NYHA class I or II at 6 months follow-up.

Statistical analysis {#Sec3}
--------------------

Continuous variables were expressed as mean ± standard deviation (SD) or as median (25th--75th percentile). Categorical variables were presented as absolute numbers and percentages. The Fisher's Exact test was used to compare unpaired categorical data. A Student *t* test was used to compare continuous variables if normally distributed and a Mann--Whitney U test if not normally distributed. Correlations were analyzed using linear regression analysis. Differences were considered statistically significant at p values \< 0.05. All statistical analyses were performed using SPSS software (IBM SPSS Statistics version 24, New York, USA).

Results {#Sec4}
=======

In total, 39 patients underwent a stress echocardiography, of whom 36 were technically successfully treated and included in the analysis. 47% was male and the mean age was 79 ± 8 years (Table [1](#Tab1){ref-type="table"}). Functional MR was present in 50% of the patients. No procedural mortality occurred and survival after 30 days and 1 year was 94% and 83% respectively. Three of the seven deceased patients died due to a cardiac cause (heart failure). Median follow-up was 551 (354--727) days. At baseline, 78% of the patients were in NYHA class III or IV. The percentage of patients in NYHA class III or IV after 1 month and 12 months was 33% and 34% respectively (Supplementary Fig. 1). MR grade 4 was present in 83% of the patients at baseline, in 15% of the patients at 1 month follow-up and in 29% of the patients at 12 month follow-up (Supplementary Fig. 2).

Table 1Baseline characteristics---data are presented as mean ± standard deviation, median (25th--75th percentile), or number (percentage)VariablePatients undergoing successful MitraClipClinical benefitNo clinical benefitp-value(n = 36)(n = 18)(n = 18)Age at procedure (years)79 ± 881 ± 877 ± 8nsMen17 (47%)9 (50%)8 (44%)nsEuroSCORE I15 ± 1216 ± 1415 ± 10nsEuroSCORE II6 ± 55 ± 47 ± 5nsClinical history Atrial fibrillation24 (67%)9 (50%)15 (83%)ns Chronic obstructive pulmonary disease5 (14%)0 (0%)5 (28%)0.045 Coronary artery disease15 (42%)5 (28%)10 (56%)ns Diabetes mellitus7 (19%)2 (11%)5 (28%)ns Previous coronary artery bypass graft9 (25%)3 (17%)6 (33%)ns Previous percutaneous coronary intervention8 (22%)3 (17%)5 (28%)ns Previous stroke5 (14%)4 (22%)1 (6%)ns Previous valve surgery1 (3%)0 (0%)1 (6%)nsNew York Heart Association class ≥ III/IV28 (78%)12 (66%)16 (89%)ns6MWT (m)321 ± 130386 ± 91255 ± 132nsVO~2~ max cycling test (mL/kg/min)11 ± 311 ± 310 ± 3nsN-terminal pro-B-type natriuretic peptide (ng/L)2337 (927--6358)1979 (1175--3869)3303 (862--7311)nsEchocardiographic variables MR grade 430 (83%)15 (83%)15(83%)ns Tricuspid regurgitation grade 44 (11%)2 (11%)2 (11%)ns MR etiologyns  Degenerative18 (50%)12 (67%)6 (33%)  Functional18 (50%)6 (33%)12 (67%) Systolic pulmonary artery pressure (mmHg)43 ± 1442 ± 1443 ± 13ns Cardiac output (L/min)4.3 ± 1.44.2 ± 1.44.4 ± 1.5ns Left ventricular ejection fraction (%)40 ± 1242 ± 1338 ± 11ns Vena contracta width (mm)6.5 ± 1.46.3 ± 1.46.7 ± 1.5nsData were available in up to 36 patients*ns* not significant

Low-dose stress echocardiography using handgrip was conducted in 15 patients, low-dose stress echocardiography using dobutamine in 6 patients and low-dose stress echocardiography using both handgrip and dobutamine in 18 patients, driven by their eligibility and consent. Findings during maximum stress were used for the analysis. The maximum stress was defined as the maximal achieved change in ejection fraction of stroke volume. Clinical benefit from MitraClip treatment (survival and NYHA I or II at 6 months follow-up) was achieved in 18 of these 36 patients.

A significant increase in Quality of Life on 4/8 subscales of the RAND Short Form-36 questionnaire was observed: Physical Functioning (p \< 0.001), Social Functioning (p \< 0.001), Mental Health (p = 0.022) and Vitality (p = 0.026) was associated with an increase in stroke volume during stress echocardiography (Fig. [1](#Fig1){ref-type="fig"}). In total, 80% of the patients with an increase in stroke volume had a stable or increased MR during stress.

Fig. 1Stroke volume. RAND Short Form-36 Quality of Life questionnaire as assessed at baseline (solid line) and 1 month after the MitraClip implantation (dotted line). The significant increased four subscales were: Physical Functioning (p \< 0.001), Social Functioning (p \< 0.001), Mental Health (p = 0.022) and Vitality (p = 0.026). **a** Patients with an increase in stroke volume (\> 40%) at baseline (n = 10); **b** patients without an increase in stroke volume (≤ 40%) at baseline (n = 25)

All seven patients with a decreased MR grade during stress \[both functional (4/7) and degenerative (3/7) MR\] remained in NYHA III or IV or died within 6 months, while 62% (18/29) of the patients with stable or increased MR during stress had clinical benefit (p = 0.008, Fig. [2](#Fig2){ref-type="fig"}).

Fig. 2MR grade. Clinical benefit is defined as survival and NYHA I or II at 6 months. Stable or increased MR during stress: clinical benefit in 62% (18/29) versus decreased MR during stress: clinical benefit in 0% (0/7) p = 0.008 (Fisher's Exact test). *LVEF* left ventricular ejection fraction, *MR* mitral regurgitation

Ejection fraction and change in ejection fraction during stress echocardiography were not associated with clinical benefit from MitraClip treatment. The stress echocardiography parameters were not significantly associated with change in 6MWT, VO~2~ max, MLHFQ, EQ-5D score or NT-proBNP levels.

Discussion {#Sec5}
==========

Our main finding is that a stable or increased MR during stress was associated with clinical benefit, while MR grade decreasing during stress was associated with limited clinical benefit. We also showed that improvement in QoL was associated with increase in stroke volume.

Stroke volume {#Sec6}
-------------

Improvement in QoL after MitraClip was associated with increase in stroke volume during stress echocardiography. Patients without increase in stroke volume (≤ 40%) had a higher heart rate in rest (83 ± 15 bpm in rest) and at maximum stress (101 ± 25 bpm) compared to those with an increase of \> 40% in stroke volume (in rest 72 ± 10 bpm; 90 ± 14 bpm during stress). Literature is inconsistent regarding the expected increase in stroke volume, which may be limited or even absent when stroke volume reaches a plateau \[[@CR21]\]. This might be the physiological explanation for patients without an increase in stroke volume. It could be that they were already in a plateau phase, therefore stroke volume per heartbeat could no longer be increased, despite stress.

Another study showed that an increase in stroke volume after MitraClip implantation (stroke volume at discharge divided by stroke volume at baseline, discharge/baseline ratio) was associated with a more favourable outcome. Further, patients with an increase in stroke volume after the MitraClip implantation had a significantly more severe MR at baseline and a significantly lower stroke volume at baseline \[[@CR22]\].

MR grade {#Sec7}
--------

A decreased MR during stress echocardiography prior to MitraClip implantation was associated with limited clinical benefit. One of the mechanisms behind this might be that the mitral annulus size reduced during stress, with an accompanying improvement of coaptation of the leaflets resulting in MR decrease. In these patients, MR might have contributed less to their complains of symptoms during exercise, explaining the lack of benefit from a technically successful MitraClip procedure.

The dynamic character of both degenerative and functional MR was in a previous study suggested as an explanation for symptoms during exercise \[[@CR23]\]. The study of Magne et al. focused on conservatively treated patients and found that increased MR during stress was associated with impaired outcome \[[@CR14]\]. Other studies had similar findings and determined an effective regurgitation orifice area by ≥ 13 mm^2^ as cut-off value \[[@CR15], [@CR24]\]. The dynamic character of MR is also noticeable in the anaesthetic-related damping of periprocedural MR which leads to underestimation of MR reduction the following day \[[@CR12]\].

Ejection fraction {#Sec8}
-----------------

An impaired LVEF in rest echocardiography was not a predictor for survival after MitraClip implantation \[[@CR5], [@CR6], [@CR25]\]. The current study showed that increase of the LVEF during stress was also not a predictor for survival after MitraClip. LVEF increase during stress was shown as an important predictor in the field of response to cardiac resynchronization therapy \[[@CR26], [@CR27]\]. On top of that, other studies in patients with MR demonstrated that LVEF increase during stress was associated with more vital ventricles and better event-free survival. We could not confirm this, probably due to low patient numbers \[[@CR28]--[@CR30]\]. It is certainly possible that the selection of the best subpopulation to get a MitraClip treatment should be based on several variables. For example, patients with contractile reserve and also a stable of increased MR during stress. This could be a subgroup with vital ventricles and also a clear contribution of the MR to their symptoms.

Considerations and limitations {#Sec9}
------------------------------

Only technically successful implantations (procedural reduction to MR grade ≤ 2) were included in the analysis as a lack of MR reduction precluded clinical benefit. Because of the limited number of patients in this analysis, further differentiation in analyses e.g. types of MR and types of stress during echocardiography was not possible. The study was a single-center study with a limited number of patients who did not all undergo a low-dose stress echocardiography with both handgrip and dobutamine. The fact that not all patients underwent a dobutamine stress echocardiography may have led to confounders.

Future research {#Sec10}
---------------

Future research should focus on patients with functional MR because of the dynamic behaviour and prevalence of this etiology. Furthermore, future research should use dobutamine stress echocardiography in all patients to prevent confounders and because of the quantitative and protocoled compared to handgrip stress echocardiography. A larger sample size is necessary to perform multivariate analysis, which is important to determine the independent predictors of clinical benefit. Moreover, a comparison between dobutamine stress echocardiography and stress testing with magnetic resonance imaging can be an interesting topic, especially regarding viability assessment.

Conclusion {#Sec11}
==========

Our main finding was that patients with a decreased MR during preprocedural stress echocardiography remained more symptomatic than patients with a stable or increased MR during stress. Therefore only patients with moderate-severe to severe MR during rest as well as during stress should be selected for MitraClip.

Further, improvement in QoL after MitraClip was associated with increase in stroke volume during stress echocardiography. Hence, stress echocardiography may support patient selection for percutaneous mitral valve repair.
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